A patient has severe P. falciparum malaria and is unable to tolerate oral medications. Which regimen is the U.S. Food and Drug Administration (FDA)approved treatment of choice for this patient?
a) Intravenous quinidine gluconate plus intravenous doxycycline Vibramycin
b) Intravenous artesunate followed by atovaquone/proguanil Malarone
c) Intravenous quinine Qualaquin plus intravenous clindamycin
d) Intravenous mefloquine plus intravenous primaquine
Question 2
A patient who frequently travels to Africa has been treated for an acute attack of P. vivax malaria. The patient asks the nurse about medications to prevent relapse. Which response by the nurse is correct?
a) The form of malaria that you have does not relapse after a clinical cure has been achieved.
b) Until you are no longer traveling to Africa, relapse drugs will be postponed.
c) Using mosquito netting and DEET when you travel will prevent relapse.
d) You will be given prophylactic medications when you travel to prevent relapse.
Measuring Patient Height
The patient's signature on the informed consent form indicates that the patient understands the
Instilling Nasal Medications
Role-Playing a Situation in Which a Patient Is Frightened, Angry, or Anxious
Oral cavity